---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-232533"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2026-05-20T20:04:03+00:00"
generated_at: "2026-05-20T21:47:39.460056+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CMS expands Medicare coverage for Personalis's NeXT Personal test to monitor neoadjuvant therapy in breast cancer

## Summary
- New coverage applies to monitoring treatment response to neoadjuvant therapy in Stage II-III TNBC or HER2+ breast cancer patients.
- Expansion effective May 19, 2026, under CMS Molecular Diagnostics Program.
- NeXT Personal is an ultrasensitive liquid biopsy test; this indication broadens addressable patient population.

## SEC filing metadata
- accession: 0001193125-26-232533
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2026-05-20T20:04:03+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000119312526232533/0001193125-26-232533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000119312526232533/psnl-20260519.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-232533
- JSON: https://secwatch.observer/filing/0001193125-26-232533.json
- Plain text: https://secwatch.observer/filing/0001193125-26-232533.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.